Tocilizumab biosimilar (Maibo Taike)

托珠单抗生物类似药（迈博太科药业）

Report date: 2024/10/28 11:21:14

Base Information

Drug NameTocilizumab biosimilar (Maibo Taike)
Drug Alias Name重组抗IL-6R人源化单克隆抗体（迈博太科药业）CMAB-806CMAB806
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionInterleukin-6 receptor alpha subunit antagonistsInterleukin-6 receptor subunit beta antagonists
TargetsInterleukin-6 receptor alpha subunitInterleukin-6 receptor subunit beta
Therapy Area/IndicationsArthritis, RheumatoidArthritis
Global Approved IndicationsArthritis, Rheumatoid
Approved Indications in ChinaArthritis, Rheumatoid
Original Approved Country/TerritoryMainland China
Original Approved Date2024/10/16
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesTaizhou Maibo Taike Biotechnology Co LtdJinyu Bowo Runze Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJinyu Bowo Runze Biotechnology Co LtdTaizhou Mabtech Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, RheumatoidArthritis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A